Corneal Ulcers Pipeline, Clinical Trials, and Key Companies | Companies – Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical

DelveInsight Business Research LLP
(United States, Nevada, Las Vegas), DelveInsight’s “Corneal Ulcer – Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Corneal Ulcer pipeline landscape.

(United States, Nevada, Las Vegas), DelveInsight’s “Corneal Ulcer – Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Corneal Ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Corneal Ulcers Pipeline Report

Over 15+ companies and 15+ pipeline drugs in Corneal Ulcers  are in various stages of development, and their anticipated acceptance in the Corneal Ulcers  market would significantly increase market revenue. 

Leading Corneal Ulcers  companies developing novel drug candidates to improve the Corneal Ulcers  treatment landscape include OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S, FirstString Research, Regeneratetx

Promising Corneal Ulcers pipeline therapies in various stages of development include VX-814, ZF874, APB, and many others.

 Corneal Ulcers Overview

A Corneal Ulcer (also known as keratitis) is an open sore on the cornea. The cornea covers the iris and the round pupil, much like a watch crystal covers the face of a watch. A corneal ulcer usually results from an eye infection, but severe dry eye or other eye disorders can cause it. A corneal ulcer, a defect of the corneal epithelium involving the underlying stroma, is a potentially vision-threatening ocular emergency.

Corneal Ulcers Pipeline Analysis: Drug Profile

CODA001: OcuNexus Therapeutics

CODA001 is an antisense oligonucleotide that down regulates the expression of the gap junction protein Cx43 which is increased in persistent epithelial defects. The first use in patients with persistent epithelial defects was reported by Ormonde et al. Five eyes with severe ocular surface burns, which were unresponsive to an established therapy, were treated by connexin43-specific antisense oligodeoxynucleotide delivered in cold, thermo reversible Poloxamer407 gel under either amniotic membrane graft or bandage contact lens. The treatment reduced inflammation within 1-2 days, and complete corneal reepithelialization was obtained in all eyes. The drug was initially being developed by CODA therapeutics and after the acquisition, OcuNexus Therapeutics is further developing the drug in the phase II stage of development.

Discover more about the emerging Corneal Ulcers drugs @ Corneal UlcersTreatment Drugs

Corneal Ulcers Pipeline Therapies and Key Companies and Therapies 

Recordati Rare Diseases: CODA001

And many others 

Corneal Ulcers Pipeline Therapeutics Assessment

DelveInsight’s Report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

The Corneal Ulcer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as









Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule




Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Corneal Ulcers Pipeline Report 

Coverage: Global 

Key Corneal Ulcers   Companies: Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical, Pfizer, Biosplice Therapeutics, Inc., Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare SA, Eurofarma Laboratorios S.A., 3SBio, Arena Pharmaceuticals, AnaptysBio, Inc., Reistone Biopharma Company Limited, Biosplice Therapeutics, Inc., LEOPharma, Intrepid Therapeutics and others.

Key Corneal Ulcers  Pipeline Therapies:  KX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 ,  CTP-543, PF-06651600 and others.

Find out more about the Corneal Ulcers treatment options in development @ Corneal Ulcers Clinical Trials

Table of Contents

1. Corneal Ulcers Introduction

2. Corneal Ulcers Executive Summary

3. Corneal Ulcers Overview

4. Corneal UlcersPipeline Therapeutics

5. Corneal UlcersLate-Stage Products (Phase III)

6. Corneal Ulcers Mid-Stage Products (Phase  II)

7. Corneal Ulcers Early Stage Products (Phase  I/II)

8. Corneal Ulcers Preclinical Stage Products

9. Corneal Ulcers Discovery Stage Products

10. Corneal Ulcers Therapeutic Assessment

11. Corneal Ulcers Inactive Products

12. Corneal Ulcers Collaborations Assessment- Licensing / Partnering / Funding

13. Corneal Ulcers Unmet Needs

14. Corneal Ulcers Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: